

Gordian Surgical Completes US\$2.25 Million Raise and Receives FDA Clearance for TroClose1200™

Company to commence commercial activity in U.S. and Europe.

Misgav, Israel; Tuttlingen, Germany – 7 December 2016 – [B. Braun Melsungen AG \(“B. Braun”\)](#), [The Trendlines Group Ltd. \(“Trendlines”\)](#) and [Gordian Surgical Ltd. \(“Gordian”\)](#) jointly announced B. Braun's lead position in Gordian's recent financing round of US\$2.25 million; Gordian is a medical portfolio company of Trendlines.

German medical device company, B. Braun led the investment round with €1 million, with the remainder from current shareholders and three venture capital funds, two of which are Chinese funds. Funds raised in this round will be used to start marketing and distribution of Gordian's TroClose1200™ in the United States (“U.S.”) and European markets.

Concurrently, with the successful fund raising round, Gordian announced it received Food and Drug Administration (“FDA”) regulatory clearance for its TroClose1200™, an innovative trocar with integrated closure system for the suturing of abdominal wall incisions during laparoscopic surgical procedures. The FDA clearance follows Gordian's receipt of Conformité Européene (“CE Mark”) certification [as announced on 6 September 2016](#).

Gordian developed TroClose1200™ to give surgeons “two-in-one” functionality: the device acts both as a trocar, through which surgical instruments enter the abdomen, and a device to close internal incisions made during surgery. The sutures are inserted into the tissue at the beginning of the procedure and anchored to remain in place throughout the operation, allowing incisions to be closed easily and quickly upon removal of the device.

In the self-same week as receiving the FDA clearance, Gordian was featured at the 32nd Annual Conference of the German Association for the Study of Obesity (DAG) e.V. in Frankfurt, where a laparoscopic procedure utilizing Gordian's TroClose1200™ was performed at The Clinic for Surgery of Obesity and Metabolic Surgery at the Sana-Klinikum Offenbach a.M. The surgery was broadcast live to surgeons from around the world gathered together in an auditorium at the conference.

Gordian began human trials in 2016 to demonstrate safety and efficacy of TroClose1200™ and to date has completed all 50 laparoscopic procedures in the clinical phase. Additionally, Gordian performed the first seven cases, defined as post-marketing surveillance, in Europe, including at the prestigious institute, IRCAD in Strasbourg, France and during the live surgery in Germany.

Professor Michel Vix, Head of the Bariatric and Metabolic Surgery Unit, University Hospital of Strasbourg, France, Scientific Co-Director, IRCAD Institute stated: “Gordian's TroClose1200™ is a very effective system, easy to use and especially useful for younger surgeons, as the learning curve is very short. TroClose1200™ has significant advantages over other gold standard closure devices on the market. Indeed, there is definitely a place for this product in the market.”

Prof. Dr. Hanns-Peter Knaebel, a member of the B. Braun Management Board and CEO of their Aesculap division, added, "Our decision to lead this investment in Gordian, a Trendlines' portfolio company, was based on the unique design of the TroClose1200™ and the great potential we see in the global laparoscopic market for a closure/trocar integrated device. We expect the TroClose1200™ to save time for surgeons and reduce anesthesia time for patients. FDA clearance, received so shortly following receipt of CE Mark, confirms our confidence in Gordian's management."

Zvi Pe'er CEO of Gordian Surgical remarks, "Receiving FDA clearance is a huge milestone in Gordian's strategic roadmap. The recent investment, led by B. Braun, allows us to move rapidly towards commercialization of our device in the U.S., Europe and other markets. Major interest in TroClose1200™ was evidenced at the recent MEDICA 2016."

About B. Braun

With over 56,000 employees in 64 countries, B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. Through constructive dialogue, B. Braun develops high quality product systems and services that are both evolving and progressive – and, in turn, improves people's health around the world. In 2015, the group generated sales of approximately €6.13 billion.

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.